Discovery of an Oleanolic Acid/Hederagenin–Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Discovery of an Oleanolic Acid/Hederagenin–Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer

Published:2019-11-13 Issue:11 Volume:82 Page:3065-3073
ISSN:0163-3864
Container-title:Journal of Natural Products
language:en
Short-container-title:J. Nat. Prod.

Author:

Chen Zhong¹,Huang Kuo-Yen²³,Ling Yong⁴^ORCID,Goto Masuo⁵^ORCID,Duan Hua-Qing¹,Tong Xiao-Hang¹,Liu Yan-Li¹,Cheng Yung-Yi⁵,Morris-Natschke Susan L.⁵,Yang Pan-Chyr⁶,Yang Shi-Lin¹,Lee Kuo-Hsiung⁵⁷^ORCID

Affiliation:

1. College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, People’s Republic of China

2. Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan

3. Graduate Institute of Health Industry Technology and Research Center for Industry of Human Ecology, Chang Gung University of Science and Technology, Taoyuan 33303, Taiwan

4. School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, People’s Republic of China

5. Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599-7369, United States

6. Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei 10617, Taiwan

7. Chinese Medicine Research and Development Center, China Medical University and Hospital, Taichung 40447, Taiwan

Funder

U.S. Department of Health and Human Services

National Natural Science Foundation of China

Priority Academic Program Development of Jiangsu Higher Education Institutions

Eshelman Institute for Innovation, University of North Carolina at Chapel Hill

Provincial Universities of Jiangsu Province Natural Science Foundation

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Complementary and alternative medicine,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Analytical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jnatprod.9b00659

Reference26 articles.

1. Cancer statistics, 2018

2. Noone, A.; Howlader, N.; Krapcho, M.; Miller, D.; Bishop, K.; Altekruse, S. F.; Kosary, C. L.; Yu, M.; Ruhl, J.; Tatalovich, Z.; Mariotto, A.; Lewis, D. R.; Chen, H. S.; Feuer, E. J.; Cronin, K. A. http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER Web site, April 2016.

3. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

4. Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms

5. Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An updated review of the pharmacological effects and potential mechanisms of hederagenin and its derivatives;Frontiers in Pharmacology;2024-06-19

2. The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer;Frontiers in Physiology;2024-03-27

3. Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight;Phytotherapy Research;2024-03-03

4. Preliminary Study on Total Component Analysis and In Vitro Antitumor Activity of Eucalyptus Leaf Residues;Molecules;2024-01-05

5. Machine Learning-Based Virtual Screening and Identification of the Fourth-Generation EGFR Inhibitors;ACS Omega;2024-01-02